MA-BRIGHTCOVE
9.2.2021 15:02:10 CET | Business Wire | Press release
Brightcove Inc. (NASDAQ: BCOV), the global leader in video for business, today announced the launch of Brightcove Cloud Playout, a new feature that enhances Brightcove’s end-to-end video platform and makes it one of the few online video providers to offer this capability. Brightcove helps propel businesses forward through video, offering a complete video ecosystem with cutting edge technology, tools, incomparable knowledge, and customer support. The launch of Cloud Playout strengthens Brightcove’s Technology and Engineering Emmy® Award-winning offerings by enabling customers to save even more time and money by consolidating all video needs on a single platform.
Brightcove Cloud Playout is a brand new feature of Brightcove Video Cloud that enables content owners and organizations to quickly and seamlessly program a scheduled playout of both on-demand video assets and live footage or events into a single stream. This provides a broadcast-grade “live TV” experience that leverages pre-recorded content to increase audience engagement and create new revenue opportunities. Customers also benefit from a highly streamlined workflow, as every possible video need is met within Brightcove’s singular all-inclusive platform.
Early adopters of this capability include long-time Brightcove client AMC, as well as global entertainment destination BookMyShow, and more. In March 2021, SXSW Online will be the first Brightcove customer to utilize Cloud Playout for its conference and festivals.
“Horror genre enthusiasts are die-hard fans, and with COVID-19 impacting Halloween celebrations we decided to host ShudderFest, a simulive 24-hour event just for them," said Mike Zagari, EP of ShudderFest. "With Brightcove's Cloud Playout, we were able to quickly pull together our content lineup and save time on our video workflows, as well as reach our global fan base by easily looping the event for every time zone around the world."
"As the ubiquitous platform for all things entertainment, BookMyShow offers several live event formats across music, comedy, theatricals performances and much more with the entire repertoire being available virtually both as both live events and pre-recorded ones such as Sunburn Home Festival, Rambo Circus and international artists including Willie Gomez, The Buckleys, Taylor Castro to name a few hosted on our live entertainment platform BookMyShow Online, powered by Brightcove,” said Parikshit Dar, Co-founder and Director, BookMyShow. "With Brightcove’s newest feature, Cloud Playout, we have been able to be a lot more flexible with our programming, and we finally have an end-to-end platform for our growing video needs."
“Since Brightcove’s inception, video innovation has been a key priority for us, and Cloud Playout demonstrates our commitment to providing our customers with the best technology and tools to help them succeed with video,” said Namita Dhallan, Chief Product Officer of Brightcove. “Cloud Playout is the next innovation in our platform, and by enabling customers to streamline the management and playout of content within a single solution, we’re saving them the additional costs and security risks of utilizing third party apps, while still providing the scalability to reach audiences around the globe, on their schedule.”
With over 50 industry-defining patents, Brightcove lives and breathes video. The company provides its game-changing video capabilities to over 3,300 customers globally. This roster includes industry leaders spanning verticals, from media titans like Showtime Networks and Vox Media, food and beverage giants such as Chick-Fil-A and Dunkin Brands, authorities in entertainment like the Academy of Motion Picture Arts and Sciences, virtual education company MasterClass, sports partners like the USGA, and many more.
About Brightcove
When video is done right, it can have a powerful and lasting effect. Hearts open. Minds change. Creativity thrives. Since 2004, Brightcove has been helping customers discover and experience the incredible power of video through its award-winning technology, empowering organizations in more than 70 countries across the globe to touch audiences in bold and innovative ways.
Brightcove achieves this by developing technologies once thought impossible, providing customer support without parallel or excuses, and leveraging the expertise and resources of a global infrastructure. Video is the world’s most compelling, exciting medium. Visit www.brightcove.com for more information. Video That Means Business.™
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005733/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom